New COVID-19 Clinical Trial Announced To Treat over 90% Of Patients With Underlying Medical Conditions

PASADENA, Calif.April 21, 2020 /PRNewswire/ -- A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives! Circularity Healthcare's trial will help some of the most at-risk patients suffering from complications due to diabetes, poor circulation, hypertension, cardiovascular disease and high blood pressure. The trial will involve the use of Circularity's already FDA-approved drug and IDE device D'OXYVA® (deoxyhemoglobin vasodilator) - a non-toxic, non-invasive microcirculation transdermal device.  It is the first biotech solution of its kind to improve overall oxygen-rich blood flow. The device has been shown to significantly heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock,  improve blood pressure and general vital organ function of the pancreas, liver, brain and kidneys, while increasing overall health for some of the most vulnerable patients.

"Anyone who suffers from an underlying condition should know that this proven treatment option is available," says Circularity Healthcare CEO Norbert Kiss. "Every medical report released so far shows that severe COVID-19 patients need blood oxygenation and blood thinners. The overwhelming majority of patients have diabetes and cardiovascular issues beyond pulmonary complications and they all have sepsis setting in early on. These are the exact main vitals and chronic diseases D'OXYVA improves like no other medication currently available on the market." Read more...